Plaintiffs have won four of seven Risperdal trials thus far, with the defendant victorious in two of them. Janssen earned a defense verdict in March, 2015 followed by what has been described as a rare dismissal mid-trial this past December, after a judge found insufficient evidence of causation submitted by the plaintiffs in the sixth Risperdal trial.
There are still about 2,300 Risperdal side effects lawsuits in the mass tort judicial pipeline housed at Philadelphia.
Risperdal and growing male breasts has been an issue reverberating through the headlines following numerous reports of men and adolescents growing male breast tissue (gynecomastia) while taking the anti-psychotic drug, prescribed for various conditions in adults, and autism in adolescents.
The plaintiff in the Risperdal lawsuit is Zachary Sabol, who filed in the Philadelphia Court of Common Pleas in April 2013. Sabol alleged he grew male breasts after having been prescribed Risperdal for ten years.
The US Food and Drug Administration (FDA) approved Risperdal in October, 2006 and eventually mandated a label change to warn of a potential 2.3 percent chance for Risperdal gynecomastia in adolescents.
READ MORE RISPERDAL LEGAL NEWS
The trial was scheduled to begin January 9. Three days prior, on January 6 the confidential settlement was announced.
There have been reports of Risperdal and Growing Male Breasts cases whereby male Risperdal patients have grown male breast tissue that in most cases can only be resolved via surgical removal. Male breasts can take an emotional toll on a patient. In rare cases, some Risperdal patients have been found to secrete.
The Risperdal side effects lawsuit is Zachary Sabol et al. v. Janssen Pharmaceuticals Inc. et al., Case No. 130402100, in the Court of Common Pleas of Philadelphia County, Pennsylvania.